TP53BP1 Antibody

What is TP53BP1 and why is it important in research?

TP53BP1 (tumor protein p53 binding protein 1, also known as 53BP1) is a critical mediator in the DNA damage response pathway. It plays a key role in the repair of double-strand DNA breaks (DSBs) by promoting non-homologous end joining (NHEJ)-mediated repair while counteracting homologous recombination (HR) repair mechanisms through its interaction with BRCA1 . TP53BP1 enhances p53-mediated transcriptional activation and functions in checkpoint signaling during mitosis .

The protein is particularly important in research related to:

• DNA damage response pathways

• Cancer biology (particularly in relation to p53 function)

• Telomere dynamics

• Immunoglobulin class-switch recombination during antibody genesis

What applications are TP53BP1 antibodies typically used for?

TP53BP1 antibodies have been validated for multiple applications:

Different applications may require optimization of dilution factors for specific experimental conditions .

What is the difference between polyclonal and monoclonal TP53BP1 antibodies?

The choice between polyclonal and monoclonal antibodies impacts experimental outcomes:

Polyclonal TP53BP1 antibodies:

• Recognize multiple epitopes of the TP53BP1 protein

• Often provide higher sensitivity but potentially lower specificity

• Examples include Rabbit polyclonal antibodies (e.g., 20002-1-AP) with affinity purification methods

• Useful when signal amplification is desired

Monoclonal TP53BP1 antibodies:

• Recognize a single epitope with high specificity

• Provide more consistent results between batches

• Examples include Rabbit monoclonal antibodies (e.g., EPR2172(2)) and Rat monoclonal antibodies (e.g., W17184B)

• Preferred for quantitative applications and when reproducibility is critical

Both types have been validated for research applications, though monoclonal antibodies often demonstrate superior specificity in knockout validation studies .

How should I optimize TP53BP1 antibody dilution for Western blot applications?

Optimization of TP53BP1 antibodies for Western blotting requires systematic approach:

• Initial dilution range testing: Begin with the manufacturer's recommended range (typically 1:500-1:50000 for TP53BP1 antibodies)

• Sample preparation considerations:

  • Use fresh cell lysates from validated positive controls (HeLa, Jurkat, K-562 cells)

  • Include proper negative controls (ideally TP53BP1 knockout cell lines)

  • Note that the observed molecular weight is approximately 450 kDa despite a calculated weight of 214 kDa

• Protocol optimization:

  • For recombinant antibodies (e.g., 83809-1-RR), higher dilutions (1:5000-1:50000) may be effective

  • For polyclonal antibodies (e.g., 20002-1-AP), lower dilutions (1:500-1:2000) are typically required

  • Consider using reducing conditions and appropriate immunoblot buffer groups

• Validation approach:

  • Test antibody specificity using peptide blocking experiments

  • Verify with known positive samples (e.g., HEK293, ZR-75 cell lines)

  • Confirm absence of signal in knockout cell lines

What are the best practices for immunofluorescence detection of TP53BP1 foci?

TP53BP1 forms distinct nuclear foci at sites of DNA damage, making it an excellent marker for DSBs. Optimal immunofluorescence detection requires:

• Cell preparation:

  • Both methanol and Triton X-100 permeabilization methods have been validated

  • Fixation with 4% paraformaldehyde followed by permeabilization is commonly used

• Antibody selection and dilution:

  • Dilution ranges of 1:125-1:1000 are recommended depending on the antibody

  • Both polyclonal (e.g., PAB18264) and monoclonal antibodies have been validated

  • Conjugated antibodies (e.g., Alexa Fluor 750-conjugated) can simplify visualization protocols

• Visualization protocol:

  • TP53BP1 localizes to the nucleus, particularly to DSB sites

  • Counterstaining with DAPI aids in nuclear localization

  • Higher antibody concentrations (3-5 μg/mL) may be necessary for clear foci detection

• Controls and validation:

  • Include untreated cells (negative control) and cells treated with DNA damaging agents (positive control)

  • Peptide blocking controls can confirm specificity

  • TP53BP1 knockout cell lines provide definitive negative controls

How should I interpret variations in molecular weight observations for TP53BP1?

Researchers frequently observe discrepancies between the calculated and observed molecular weights of TP53BP1:

• Expected vs. observed weight:

  • Calculated molecular weight: 214 kDa

  • Observed molecular weight: ~450 kDa on SDS-PAGE

• Factors contributing to this discrepancy:

  • Post-translational modifications including phosphorylation and methylation

  • The presence of multiple isoforms (up to 3 different isoforms have been reported)

  • Structural characteristics affecting migration patterns in gel electrophoresis

• Validation approaches:

  • The discrepancy is consistent across antibodies from different vendors

  • Confirm using TP53BP1 knockout cell lines as negative controls

  • Compare with other established antibodies targeting different epitopes

• Experimental considerations:

  • Use appropriate molecular weight markers spanning the 200-500 kDa range

  • Optimize gel percentage (typically use lower percentage gels, 6-8%)

  • Document the observed molecular weight in your specific experimental system

How can TP53BP1 antibodies be utilized to study DNA damage response pathways?

TP53BP1 serves as a critical marker for DSB repair pathway choice, making its antibodies valuable tools:

• Mechanistic studies of DSB repair:

  • TP53BP1 promotes NHEJ over HR repair pathways

  • Visualize recruitment to H2AK15Ub and H4K20me2 histone marks at DSB sites

  • Monitor interactions with other repair proteins (RIF1, NUDT16L1/TIRR)

• Experimental approaches:

  • Time-course immunofluorescence to track TP53BP1 foci formation and resolution

  • Co-immunoprecipitation with TP53BP1 antibodies to identify interaction partners

  • Chromatin immunoprecipitation (ChIP) to map TP53BP1 binding sites

• Quantitative analysis techniques:

  • Measure foci number, size, and intensity as indicators of DSB burden

  • Correlate with cell cycle markers to analyze phase-specific responses

  • Combine with other DSB markers (γH2AX, MDC1) for comprehensive pathway analysis

• Applications in cancer research:

  • Assess DNA repair defects in tumor samples

  • Study synthetic lethality in BRCA-deficient cancers

  • Investigate resistance mechanisms to PARP inhibitors and other genotoxic therapies

What considerations are important when using TP53BP1 antibodies for multi-parameter flow cytometry?

Incorporating TP53BP1 in flow cytometry requires specific technical considerations:

• Cell preparation and fixation:

  • Thorough permeabilization is critical for nuclear antigen access

  • Standard recommendation: 0.25 μg antibody per 10^6 cells in 100 μL suspension

  • Fix cells in 2-4% paraformaldehyde followed by permeabilization with 0.1-0.5% Triton X-100

• Antibody selection:

  • Use flow cytometry-validated antibodies (check RRID numbers, e.g., AB_2820202)

  • Consider directly conjugated antibodies for multi-parameter analysis

  • If using unconjugated primary antibodies, select secondary antibodies with minimal spectral overlap

• Panel design considerations:

  • TP53BP1 is often paired with cell cycle markers (e.g., DAPI, propidium iodide)

  • Co-stain with γH2AX for comprehensive DSB analysis

  • Include markers for specific cell populations of interest

• Controls and validation:

  • Use isotype controls (e.g., Rabbit/Rat IgG)

  • Include TP53BP1-null cells as negative controls when possible

  • Perform fluorescence-minus-one (FMO) controls to set proper gating

How can researchers troubleshoot contradictory results when using different TP53BP1 antibodies?

Discrepancies between results obtained with different TP53BP1 antibodies can arise from several factors:

• Epitope differences:

  • Antibodies targeting different regions of TP53BP1 may yield varying results

  • Example: Antibody 83809-1-RR targets a specific region while ab36823 recognizes amino acids 350-400

  • Post-translational modifications may mask certain epitopes in context-dependent manner

• Systematic validation approaches:

  • Test multiple antibodies in parallel on the same samples

  • Verify antibody specificity using knockout/knockdown controls

  • Cross-validate with orthogonal techniques (e.g., mass spectrometry)

• Technical optimization:

  • Compare different fixation and antigen retrieval methods:

    • TE buffer pH 9.0 vs. citrate buffer pH 6.0 for IHC applications

    • Different permeabilization approaches for ICC/IF

  • Optimize blocking conditions to reduce background

  • Test antibody performance across different lots

• Data interpretation strategies:

  • Prioritize results from antibodies with the most extensive validation

  • Consider the biological context and specific pathway being studied

  • Document all technical parameters to enable accurate replication

How can TP53BP1 antibodies be employed in studying immunoglobulin class-switch recombination?

TP53BP1 plays a crucial role in immunoglobulin class-switch recombination (CSR), making it valuable for immunology research:

• Biological significance:

  • TP53BP1 is required for CSR during antibody genesis

  • It participates in repair and orientation of broken DNA ends during this process

  • Unlike classical NHEJ and V(D)J recombination, CSR specifically requires TP53BP1

• Experimental approaches:

  • Immunofluorescence to visualize TP53BP1 recruitment to switch regions

  • ChIP assays to identify TP53BP1 binding at immunoglobulin loci

  • Functional assays measuring class switching efficiency in the presence of TP53BP1 antibodies

• Cell models:

  • B lymphocytes (primary or cell lines) undergoing activation

  • Lymphocyte populations isolated from mouse models

  • Human lymphocyte samples from normal and immunodeficient patients

• Combined markers:

  • Co-stain with AID (activation-induced cytidine deaminase)

  • Use antibodies against specific immunoglobulin isotypes

  • Combine with cell proliferation markers

What are the considerations for using TP53BP1 antibodies in multiplex immunofluorescence studies?

Multiplex detection involving TP53BP1 requires careful planning:

• Antibody compatibility:

  • Select antibodies raised in different host species to avoid cross-reactivity

  • Consider using directly conjugated antibodies with minimal spectral overlap

  • Validate each antibody individually before combining in multiplex assays

• Staining protocols:

  • Sequential staining may be necessary for multiple rabbit antibodies

  • Optimize antibody concentration for each marker to achieve balanced signal intensity

  • Consider tyramide signal amplification for weak signals

• Recommended combinations:

  • TP53BP1 + γH2AX for comprehensive DSB detection

  • TP53BP1 + BRCA1 to distinguish between NHEJ and HR pathways

  • TP53BP1 + cell cycle markers (e.g., CyclinA) to analyze cell cycle-specific responses

• Image acquisition and analysis:

  • Use appropriate filters to minimize bleed-through

  • Employ computational approaches for colocalization analysis

  • Consider machine learning algorithms for automated foci counting

How should researchers design validation experiments to confirm TP53BP1 antibody specificity?

Comprehensive validation of TP53BP1 antibodies is essential for reliable research:

• Genetic approaches:

  • Test antibodies on TP53BP1 knockout cell lines (e.g., CRISPR/Cas9-edited HeLa cells)

  • Compare signal in wildtype vs. knockout samples by Western blot, IF, and flow cytometry

  • Use siRNA/shRNA knockdown as an alternative approach

• Biochemical validation:

  • Peptide competition assays using the immunizing peptide

  • Orthogonal detection methods (e.g., mass spectrometry)

  • Immunoprecipitation followed by Western blot with antibodies to different epitopes

• Functional validation:

  • Verify proper localization pattern (nuclear, with foci formation after DNA damage)

  • Confirm expected molecular weight, accounting for the discrepancy (~450 kDa observed vs. 214 kDa calculated)

  • Test reactivity across multiple cell lines where TP53BP1 is expressed (HeLa, Jurkat, K-562)

• Documentation and reporting:

  • Record antibody catalog numbers, lot numbers, and RRID identifiers

  • Document detailed experimental conditions and validation results

  • Include appropriate validation controls in published research

How might emerging techniques enhance the utility of TP53BP1 antibodies in research?

Several innovative approaches are expanding the applications of TP53BP1 antibodies:

• Live-cell imaging technologies:

  • Development of cell-permeable fluorescently tagged nanobodies against TP53BP1

  • CRISPR-mediated tagging of endogenous TP53BP1 to avoid artifacts of antibody staining

  • Correlation with other live-cell DNA damage markers

• Super-resolution microscopy:

  • Improved spatial resolution of TP53BP1 foci structure

  • Analysis of nanoscale colocalization with other repair factors

  • 3D reconstruction of DNA damage response architecture

• Single-cell applications:

  • Integration of TP53BP1 detection in single-cell proteomics

  • Spatial transcriptomics combined with TP53BP1 immunofluorescence

  • High-throughput screening approaches for DNA repair modulators

• Clinical research applications:

  • Development of diagnostic applications for cancer stratification

  • Predictive biomarkers for response to DNA damage-inducing therapies

  • Patient-derived organoid analysis for personalized medicine approaches

What are the critical considerations when analyzing TP53BP1 post-translational modifications?

Post-translational modifications (PTMs) significantly influence TP53BP1 function:

• Key PTMs affecting TP53BP1:

  • Phosphorylation by ATM kinase after DNA damage

  • Methylation events that regulate protein interactions

  • Ubiquitination that affects protein stability and localization

• Antibody selection for PTM studies:

  • Use antibodies specifically recognizing phosphorylated TP53BP1

  • Consider the epitope location relative to known modification sites

  • Validate antibody specificity using phosphatase treatments

• Experimental approaches:

  • Phospho-specific Western blotting

  • Mass spectrometry for comprehensive PTM mapping

  • Time-course analysis after DNA damage induction

• Biological significance:

  • Phosphorylation promotes interaction with RIF1 and dissociation from NUDT16L1/TIRR

  • PTMs regulate recruitment to DNA damage sites

  • Modifications influence pathway choice between NHEJ and HR

How can researchers integrate computational approaches with TP53BP1 antibody-based experiments?

Computational methods enhance the depth and reproducibility of TP53BP1 research:

• Image analysis algorithms:

  • Automated foci counting and characterization

  • Machine learning approaches for pattern recognition

  • 3D reconstruction of nuclear architecture

• Systems biology integration:

  • Network analysis of TP53BP1 interactions

  • Pathway modeling of DNA damage response dynamics

  • Integration with genomic and transcriptomic data

• Predictive modeling:

  • Structure-based prediction of antibody binding sites

  • Simulation of DNA repair pathway dynamics

  • Virtual screening for compounds targeting TP53BP1-dependent processes

• Quantitative approaches:

  • Statistical methods for analyzing foci distribution

  • Mathematical modeling of repair kinetics

  • Bayesian frameworks for integrating multiple data types